Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification?

Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy

“…A generic, unique score for assessing histological tumor response to chemotherapy in PM makes sense because of the clinical impact of histological response to therapy and because the organ of metastasis (peritoneum) is the same [ 3 ]. The PRGS has been the object of a multi-institutional validation study [ 4 ] and is now diffusing into clinical practice [ 8 , 14 ], [ 15 ], [ 16 ], [ 17 ], [ 18 ], [ 19 ], [ 20 ]. The PRGS is increasingly used as secondary [ 21 ], [ 22 ], [ 23 ], [ 24 ], or even as primary outcome criteria [ 25 ] in clinical studies on PM.…”

Evaluation of the environmental contamination and exposure risk in medical/non-medical staff after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy

“…The standardized surgical technique includes a two-port access with double-balloon trocars and aerosolization of the chemotherapeutic drug after evaluation of the metastatic disease, as described elsewhere (Hübner et al, 2017). In PIPAC-Ox, oxaliplatin (92mg.m -2 ) is diluted in 5% glucose solution, and administered with a flow of 0.6ml.sec -1 and upstream pressure limit of 290 psi (Dumont et al, 2020;Sgarbura et al, 2020). The total administration time is 37 minutes.…”

Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)

“…Compared to baseline, urinary frequency worsened 1 week after the first procedure (MD + 13 [95% CI [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22], p = 0.004, CD 0.74, moderate deterioration) and returned to baseline at subsequent time points (Fig. 3E).…”